Drug-resistant malaria in Myanmar: A call for increased funding to prevent a global catastrophe


The CDC estimates there are 198 million cases of malaria that occur worldwide with more than 500,000 people dying from the disease every year. Although this disease has slowly declined in recent years, experts believe that certain endemic areas could still be at high risk for drug resistance. One such area includes Myanmar, a Southeast Asian region located on the border between India and China.

Myanmar is a high-risk area for malaria

Myanmar is a high-risk area for artemisinin resistant malaria

Over 76% of Myanmar’s population lives in regions stricken with poverty and poor health infrastructure that contribute to the mass spread of disease in areas where malaria is endemic. This area in particular is becoming resistant to artemisinin, the first line of defense. Experts suggest Myanmar is a priority region for the elimination of artemisinin resistant malaria (ARM) in order to avoid the international disaster that would result if ARM were to spread to India and Africa. Immediate and large-scale action along with substantial financial support from multiple stakeholders is needed to prevent further spread of ARM and avoid a looming malaria catastrophe. The Burmese government estimates that it will need US$1.2 billion over the next 15 years or $80 million per annum. The proposed solution would strengthen surveillance, increase rapid diagnostic testing and create new drugs to combat ARM. However, recently the Australian government, one of the 3MDG Fund donors, the largest development fund in Myanmar, has decided to cancel its pledged sum of $42 million in aid to the country. The implications of this withdrawal are uncertain and untimely.

With the ability of the malaria parasite to thwart off once effective drugs, the fear of widespread resistance is now a reality. Scientists believe we have a small window of opportunity to support Myanmar’s national campaign to increase funding to prevent a global health disaster and achieve Myanmar’s 2030 malaria elimination goals.

3 Responses to “Drug-resistant malaria in Myanmar: A call for increased funding to prevent a global catastrophe”

  1. mbarna0523 Says:

    Excellent post. I was wondering exactly to whom and for what you’re advocating? Are you looking for Australia to restore the missing $42M? IMF or WHO monetary support? Will Myanmar increase their portion of the proposed $1.2B? I think directing your advocacy towards a specific institution/country may yield better results.

  2. sbfphc Says:

    Drug resistance to antimicrobial drugs (including antimalarials and antibiotics) does threaten to erase many public health gains. Resistance to both cholroquine and sulfadoxine-pyrimethamine arose from southeast Asia, but we were lucky to find artemisinin based drugs to fill that gap. Unfortunately substitutes are not far along in the pipeline should artemisinin-based combination therapy fail. We need to consider the role the the behavior of prescribers and patients plays in ostering drug resistance and mount active education for both groups.

  3. Drug-resistant malaria in Myanmar: A call for increased funding to prevent a global catastrophe « Tropical Health Matters Says:

    […] are happy to re-post a blog by Alice Sowinski, Craigen Nes, and Diane Del Pozo in the SBFPHC Policy Advocacy Blog of the Social and Behavioral Foundations of Primary Health Care Course at the Johns Hopkins […]

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: